Pramlintide, marketed as Symlin, is a synthetic analog of amylin and the only amylin-based agent currently FDA-approved. It is indicated as an adjunct to mealtime insulin in adults with type 1 or type 2 diabetes who have not achieved adequate glycemic control on insulin alone.
This guide situates Pramlintide within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.
What is pramlintide?
Pramlintide is a synthetic peptide analog of human amylin, modified at three positions with proline substitutions to prevent the aggregation that makes native human amylin unusable as a drug.
It is administered by subcutaneous injection before meals, separately from insulin — the two cannot be mixed in the same syringe. In type 1 diabetes it addresses a genuine deficiency: beta cell destruction eliminates amylin along with insulin, so patients lack both hormones while conventional therapy replaces only one.
How pramlintide works
Pramlintide acts at amylin receptors in the hindbrain and produces three relevant effects: it slows gastric emptying, it suppresses inappropriate post-meal glucagon secretion, and it promotes satiety.
The glucagon effect deserves particular attention. In diabetes, glucagon is often inappropriately elevated after meals, driving hepatic glucose output at exactly the wrong moment and worsening the post-prandial excursion. Pramlintide addresses that specific defect, which insulin alone does not.
The consequence is that pramlintide targets the post-meal glucose curve rather than fasting glucose — a complement to, not a substitute for, basal insulin coverage.
Safety and the boxed warning
Pramlintide carries a boxed warning for severe hypoglycemia, and the mechanism of that risk must be understood precisely. Pramlintide does not itself cause hypoglycemia. It causes hypoglycemia in combination with insulin, because slowed gastric emptying delays carbohydrate absorption while the mealtime insulin dose acts on its original schedule. Insulin arrives before the glucose does.
The mitigation is therefore procedural, not incidental: mealtime insulin doses require substantial reduction when pramlintide is initiated, with careful re-titration. Severe hypoglycemia with pramlintide typically occurs within the first hours after dosing and is most likely early in therapy.
Nausea is the other prominent effect, generally worst at initiation and improving with gradual dose escalation. It is contraindicated in patients with confirmed gastroparesis and in those with hypoglycemia unawareness — both directly related to the mechanisms above.
Where pramlintide fits today
Pramlintide's use is limited in practice. It requires additional injections separate from insulin, demands careful insulin dose reduction, and produces weight reduction that is real but modest. Its adoption has been correspondingly narrow.
Its significance is nonetheless substantial: it is the clinical proof of concept that amylin signaling is a viable therapeutic pathway. That validation is the foundation for long-acting amylin analogs such as cagrilintide, now being developed for weight management with weekly dosing and, in combination products, considerably larger effects.
Learn peptides the right way
Empire Medical Training's Peptide Therapy Master Course is a CME-accredited program covering amylin and incretin satiety physiology, patient selection, monitoring, regulatory status, and compliant sourcing — taught by board-certified physicians. Available in person and via livestream. It is also Course 1 of Empire’s Peptide Therapy Certification, which adds business, marketing and healthcare-law training, a documented case series and a final exam.
Explore the Certification →